APA (7th ed.) Citation

L, R., RK, K., T, M., BY, R., P, M., JW, P., . . . GK, A. (2021). Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. Liver cancer, 11(1), 38. https://doi.org/10.1159/000519867

Chicago Style (17th ed.) Citation

L, Rimassa, et al. "Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib Versus Placebo in Advanced Hepatocellular Carcinoma." Liver Cancer 11, no. 1 (2021): 38. https://doi.org/10.1159/000519867.

MLA (9th ed.) Citation

L, Rimassa, et al. "Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib Versus Placebo in Advanced Hepatocellular Carcinoma." Liver Cancer, vol. 11, no. 1, 2021, p. 38, https://doi.org/10.1159/000519867.